GPR30: a novel indicator of poor survival for endometrial carcinoma
Journal, Book or Conference Title
American Journal of Obstetrics and Gynecology
OBJECTIVE: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. STUDY DESIGN: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. RESULTS: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). CONCLUSION: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.
Adult, Aged, Biopsy, Needle, Cohort Studies, Endometrial Neoplasms/genetics/mortality/pathology, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Staging, Probability, Prognosis, Receptors, Estrogen/biosynthesis, Receptors, G-Protein-Coupled/biosynthesis/genetics/metabolism, Risk Assessment, Sensitivity and Specificity, Statistics, Nonparametric, Survival Analysis, Tumor Markers, Biological/analysis
NLM Title Abbreviation
Am J Obstet Gynecol
This document is currently not available here.